Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.
Calluna Pharma is an Oslo-based clinical-stage biotech building first-in-class antibodies that switch off the upstream signals driving inflammation and fibrosis. Formed in 2024 from the merger of Oxitope Pharma and Arxx Therapeutics and backed by a EUR 75 million Series A, the company targets damage-associated molecular patterns (DAMPs) such as S100A4 to halt diseases like idiopathic pulmonary fibrosis at their root rather than managing symptoms.
Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.
Olatec Therapeutics is a clinical-stage biopharmaceutical company in New York developing a platform of oral NLRP3 inflammasome inhibitors to treat acute and chronic inflammatory diseases. Its lead compound, dapansutrile (OLT1177), is a selective small-molecule NLRP3 inhibitor that has shown clinical benefit and a clean safety profile across gout, heart failure and a broad range of inflammatory and neuroinflammatory conditions, positioning oral inflammasome blockade as a potential alternative to injectable IL-1 biologics.
Vishal Patel is the co-founder and CEO of Triveni Bio, a Watertown, Massachusetts biotech betting that genetics, not trial-and-error, should decide which antibodies reach patients with immune and inflammatory diseases. He stitched the company together from a two-startup merger, raised more than $200 million across Series A and B rounds, and pointed its lead programs at the skin enzymes behind atopic dermatitis. A Harvard PhD and MIT MBA who once helped draft healthcare legislation on Capitol Hill and still serves as a US Navy reservist, Patel runs a lab while keeping a foot in venture as an Atlas advisor.
Yang Liu is a cancer immunologist turned serial biotech founder who chairs and runs OncoC4, the Rockville, Maryland company developing next-generation immune checkpoint antibodies. After decades as an endowed professor at NYU, Ohio State, Michigan, and beyond, he co-founded OncoImmune (acquired by Merck for $425M) and then OncoC4, whose lead anti-CTLA-4 antibody gotistobart is in late-stage development with BioNTech. He left full-time academia to take his own discoveries from the bench into patients.
BreezeBio (formerly GenEdit) is a Brisbane, California-based biotechnology company that develops precision genetic medicines using its proprietary NanoGalaxy platform - a library of polymer nanoparticles capable of delivering genetic payloads like mRNA, siRNA, and CRISPR components to specific tissues without triggering immune responses. Unlike viral vectors that can only be dosed once and often provoke dangerous immune reactions, BreezeBio's non-viral approach allows repeat dosing, broad payload flexibility, and tissue selectivity across immune cells, heart, lung, and CNS. Founded in 2016 out of UC Berkeley by CEO Dr. Kunwoo Lee and CTO Dr. Hyo Min Park, the company rebranded from GenEdit in early 2026 following its $60M Series B, signaling a shift from delivery-platform licensor to full therapeutic developer with a lead program (BRZ-101) targeting Type 1 Diabetes.
Jennifer Cygan is a seasoned biotech executive and Chief Business Officer at EpiBiologics, where she helps advance a pipeline of novel bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. With a Ph.D. from Harvard and over two decades of business leadership in biotechnology, she has been a pivotal force at Genentech, Calico Life Sciences (managing a $2.5B AbbVie alliance), and has co-founded and served as CBO for multiple emerging biotech companies including Broadwing Bio, Eikon Therapeutics, GenEdit, and Plexium. Her career sits at the intersection of science and strategy - translating cutting-edge biology into deals, partnerships, and companies that matter.
Dr. Judy Chou is the President, CEO, and Board Member of AltruBio Inc., a clinical-stage biotech company in San Francisco pioneering a first-in-class immune checkpoint enhancer platform targeting PSGL-1/CD162 to treat autoimmune diseases. With over 25 years of experience spanning Bayer Pharmaceuticals, Pfizer, Genentech, and Wyeth, she led AltruBio through a landmark $225M Series B financing in 2024 and is advancing lead candidate ALTB-268 through Phase 2 trials for ulcerative colitis. Recognized as one of Endpoints News' Top 20 Women in Biopharma (2025) and a Most Influential Women in Business honoree (San Francisco Business Times, 2018), she holds a Ph.D. from Yale University and conducted post-doctoral training at the Max-Planck Institute in Germany.
Adam Rosenthal is the CEO and Founder of Star Therapeutics, a clinical-stage biotech he launched in 2018 with a mission to develop life-changing therapies for rare diseases. An MIT and Harvard-trained biomedical engineer, Rosenthal built Star around the insight that shared biology across multiple rare diseases can yield single therapies addressing many conditions at once. His lead asset VGA039 - a first-in-class monoclonal antibody targeting Protein S - entered Phase 3 trials in 2025 for von Willebrand disease, the most common inherited bleeding disorder. Star has raised over $315 million from top-tier life sciences investors including Sanofi Ventures and Viking Global Investors.
Sandra Pérez Baos, Ph.D. is a Senior Associate at 2048 Ventures, a NYC- and Boston-based thesis-driven early-stage VC firm that closed an oversubscribed $82M Fund III in January 2026. A scientist turned investor, she brings a decade of hands-on experience in translational immunology and molecular biology research - first as a postdoctoral researcher at NYU Grossman School of Medicine, then as a founding leader at Nucleate New York, and later as a fellow with NYU's technology commercialization office. At 2048 Ventures she leads biotech and health investments at pre-seed and seed stages, writing checks from $500K to $3M into companies building the next generation of platform biology, drug delivery, diagnostics, and digital health.
Katherine J. Wu, Ph.D. is a staff science writer at The Atlantic and one of the most respected science journalists working today. A former Harvard bacteriologist turned acclaimed writer, she translates complex biology - from pandemic viruses to the sex lives of deep-sea creatures - into stories that are simultaneously rigorous and riveting. Winner of the 2024 Kovler Prize and the 2022 Schmidt Award for Science Communication, she has reported for The New York Times, National Geographic, and Smithsonian, and holds a PhD in Microbiology and Immunobiology from Harvard. She writes the newsletter The Pivot, covering science and health.